Evelo Biosciences, Inc. (EVLO)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Feb 23, 2026
-96.00%
Market Cap 1.90K
Revenue (ttm) n/a
Net Income (ttm) -82.35M
Shares Out 18.98M
EPS (ttm) -9.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 4,210
Open 0.0001
Previous Close n/a
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.0020
Beta 0.52
RSI 43.06
Earnings Date Mar 16, 2026

About Evelo Biosciences

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 66
Stock Exchange OTCMKTS
Ticker Symbol EVLO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.